Curated News
By: NewsRamp Editorial Staff
July 31, 2025
Oragenics Advances Concussion Treatment with Phase IIa Trial of ONP-002
TLDR
- Oragenics partners with Southern Star Research for Phase IIa trial of ONP-002, offering investors a unique opportunity in the burgeoning field of intranasal neurological treatments.
- Oragenics' Phase IIa trial for ONP-002 is a randomized, double-blind, placebo-controlled study assessing safety and efficacy in mild traumatic brain injury treatment through intranasal delivery.
- Oragenics' ONP-002 trial represents hope for millions affected by mild traumatic brain injury, aiming to improve treatment outcomes and quality of life.
- Discover how Oragenics is pioneering intranasal drug delivery for brain injuries, a novel approach that could revolutionize concussion treatment.
Impact - Why it Matters
This development is crucial as it represents a potential breakthrough in the treatment of mild traumatic brain injuries, a condition with limited therapeutic options. The success of ONP-002 could significantly improve recovery outcomes for individuals suffering from concussions, offering a safer and more effective treatment option. Additionally, this trial underscores the importance of innovative drug delivery systems in addressing complex neurological conditions, paving the way for future advancements in the field.
Summary
Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company, has partnered with Southern Star Research to advance the Phase IIa trial of ONP-002, a novel intranasal neurosteroid aimed at treating mild traumatic brain injury (mTBI). This collaboration marks a significant milestone in addressing the unmet needs in concussion treatment, with the study set to evaluate the safety, tolerability, and efficacy of ONP-002. The trial, which has received Human Research Ethics Committee approval in Australia, is in the final stages of site selection and patient enrollment preparation. Oragenics' CEO, Janet Huffman, emphasizes the importance of this partnership in the development of ONP-002. For more details, visit the full press release.
Oragenics is at the forefront of developing nasal delivery solutions for neurological conditions and infectious diseases, including treatments for mTBI and Niemann Pick Disease Type C (NPC). The company's innovative approach includes proprietary powder formulations and an intranasal delivery device. Investors and interested parties can find more information on Oragenics' website and through the InvestorBrandNetwork, which provides comprehensive coverage and updates on OGEN and other investment opportunities.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Advances Concussion Treatment with Phase IIa Trial of ONP-002
